Education
About Us
Working with TipRanks
Follow Us
Moderna (MRNA)
NASDAQ:MRNA
MRNA Analyst Ratings
Hold
2 Buy
13 Hold
3 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
MRNA Stock 12 Month Forecast
Average Price Target
$44.23
▲(60.60% Upside)
| Highest Price Target$198.00 | Average Price Target$44.23 | Lowest Price Target$15.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Bernstein
―
Hold
―
Reiterated
09/30/25
Brookline Capital Markets
$198
Buy
618.95%
Upside
Reiterated
09/23/25
William Blair
―
Hold
―
Reiterated
09/22/25
UBS
$70
Buy
154.18%
Upside
Reiterated
09/22/25
Argus Research
―
Hold
―
Reiterated
08/29/25
Leerink Partners
$18→$15
Sell
-45.53%
Downside
Reiterated
08/22/25
Evercore ISI
$32
Hold
16.19%
Upside
Reiterated
08/04/25
Bank of America Securities
$25→$24
Sell
-12.85%
Downside
Reiterated
08/04/25
Goldman Sachs
$35
Hold
27.09%
Upside
Reiterated
08/04/25
Citi
$35→$30
Hold
8.93%
Upside
Reiterated
08/04/25
Morgan Stanley
$31
Hold
12.56%
Upside
Reiterated
08/04/25
Barclays
$40→$31
Hold
12.56%
Upside
Reiterated
08/04/25
Berenberg Bank
$30
Hold
8.93%
Upside
Reiterated
08/04/25
Needham
―
Hold
―
Reiterated
08/01/25
Moderna's Hold Rating: Navigating Revenue Volatility and Strategic Shifts Amidst Pipeline PotentialWe believe MRNA's vaccine franchise (COVID, RSV , Flu, etc.) will continue to face headwinds in the near term. The rare disease pipeline is intriguing but not yet a major value driver. We believe the oncology pipeline has the most upside potential, but we don't expect major data catalysts from this program until 2026+. Maintain Hold. Disclaimers JOSEPH STRINGER, PH.D.
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Bernstein
―
Hold
―
Reiterated
09/30/25
Brookline Capital Markets
$198
Buy
618.95%
Upside
Reiterated
09/23/25
William Blair
―
Hold
―
Reiterated
09/22/25
UBS
$70
Buy
154.18%
Upside
Reiterated
09/22/25
Argus Research
―
Hold
―
Reiterated
08/29/25
Leerink Partners
$18→$15
Sell
-45.53%
Downside
Reiterated
08/22/25
Evercore ISI
$32
Hold
16.19%
Upside
Reiterated
08/04/25
Bank of America Securities
$25→$24
Sell
-12.85%
Downside
Reiterated
08/04/25
Goldman Sachs
$35
Hold
27.09%
Upside
Reiterated
08/04/25
Citi
$35→$30
Hold
8.93%
Upside
Reiterated
08/04/25
Morgan Stanley
$31
Hold
12.56%
Upside
Reiterated
08/04/25
Barclays
$40→$31
Hold
12.56%
Upside
Reiterated
08/04/25
Berenberg Bank
$30
Hold
8.93%
Upside
Reiterated
08/04/25
Needham
―
Hold
―
Reiterated
08/01/25
Moderna's Hold Rating: Navigating Revenue Volatility and Strategic Shifts Amidst Pipeline PotentialWe believe MRNA's vaccine franchise (COVID, RSV , Flu, etc.) will continue to face headwinds in the near term. The rare disease pipeline is intriguing but not yet a major value driver. We believe the oncology pipeline has the most upside potential, but we don't expect major data catalysts from this program until 2026+. Maintain Hold. Disclaimers JOSEPH STRINGER, PH.D.
Best Analysts Covering Moderna
1 Month
xxx
Success Rate
28/45 ratings generated profit
Average Return
+0.81%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 62.22% of your transactions generating a profit, with an average return of +0.81% per trade.
3 Months
xxx
Success Rate
28/45 ratings generated profit
Average Return
-5.79%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 62.22% of your transactions generating a profit, with an average return of -5.79% per trade.
1 Year
Success Rate
35/45 ratings generated profit
Average Return
-2.31%
reiterated a sell rating 2 months ago
Copying Mani Foroohar's trades and holding each position for 1 Year would result in 77.78% of your transactions generating a profit, with an average return of -2.31% per trade.
2 Years
xxx
Success Rate
39/45 ratings generated profit
Average Return
+31.46%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 86.67% of your transactions generating a profit, with an average return of +31.46% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
MRNA Analyst Recommendation Trends
Rating
Jun 25
Jul 25
Aug 25
Sep 25
Oct 25
Strong Buy
6
6
4
6
5
Buy
0
0
0
0
0
Hold
42
45
44
32
22
Sell
8
9
9
6
3
Strong Sell
0
0
0
0
0
total
56
60
57
44
30
Each month's total comprises the sum of three months' worth of ratings.
MRNA Financial Forecast
MRNA Stock Forecast FAQ
What is MRNA’s average 12-month price target, according to analysts?
Based on analyst ratings, Moderna’s 12-month average price target is 44.23.
What is MRNA’s upside potential, based on the analysts’ average price target?
Moderna has 60.60% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is MRNA a Buy, Sell or Hold?
Moderna has a consensus rating of Hold which is based on 2 buy ratings, 13 hold ratings and 3 sell ratings.
What is Moderna’s price target?
The average price target for Moderna is 44.23. This is based on 18 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $198.00 ,the lowest forecast is $15.00. The average price target represents 60.60% Increase from the current price of $27.54.
The highest analyst price target is $198.00 ,the lowest forecast is $15.00. The average price target represents 60.60% Increase from the current price of $27.54.
What do analysts say about Moderna?
Moderna’s analyst rating consensus is a Hold. This is based on the ratings of 18 Wall Streets Analysts.
How can I buy shares of MRNA?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.